All In Biotech

Drug Trial Radar · NCT00628628

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

Jan 2008

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sanofi
First posted
Mar 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: To determine the efficacy of rasburicase administered as a single dose followed by as needed dosing (investigational arm) as compared to fixed dosing for 5 days (standard treatment arm) in the treatment of patients at high risk or potential risk for tumor lysis syndrome. Secondary Objectives: 1. To evaluate the plasma uric acid area under the curve (AUC) from baseline through 7 days 2. To evaluate the incidence of renal insufficiency and electrolyte abnormalities. 3. To determine the safety and immunogenicity of rasburicase. 4. To evaluate the cost-effectiveness of the experimental treatment (investigational arm).

Conditions

  • Tumor Lysis Syndrome

Interventions

  • As Needed RasburicaseDrug

    .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.

  • Fixed Dose RasburicaseDrug

    .15 mg/kg IV Over 30 Minutes Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Plasma Uric Acid (UA) ResponseTime frame: First cycle of chemotherapy, up to 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.